The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

MLA

Ferru, A., et al. “The Status of CDKN2A Alpha (P16INK4A) and Beta (P14ARF) Transcripts in Thyroid Tumour Progression.” British Journal of Cancer, vol. 95, no. 12, Dec. 2006, pp. 1670–77. EBSCOhost, https://doi.org/10.1038/sj.bjc.6603479.

APA

Ferru, A., Fromont, G., Gibelin, H., Guilhot, J., Savagner, F., Tourani, J. M., Kraimps, J. L., Larsen, C. J., & Karayan-Tapon, L. (2006). The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. British Journal of Cancer, 95(12), 1670–1677. https://doi.org/10.1038/sj.bjc.6603479

Chicago

Ferru, A, G Fromont, H Gibelin, J Guilhot, F Savagner, J M Tourani, J L Kraimps, C J Larsen, and L Karayan-Tapon. 2006. “The Status of CDKN2A Alpha (P16INK4A) and Beta (P14ARF) Transcripts in Thyroid Tumour Progression.” British Journal of Cancer 95 (12): 1670–77. doi:10.1038/sj.bjc.6603479.